CVS Health (CVS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
3 Apr, 2026Executive summary
Annual Meeting scheduled for May 14, 2026, at 8:00 A.M. ET, to be held virtually for shareholder participation.
Shareholders are encouraged to vote in advance or during the virtual meeting, with materials available online or by request.
Voting matters and shareholder proposals
Election of 13 directors is up for shareholder vote, with all nominees recommended by the board.
Ratification of the appointment of the independent registered public accounting firm for 2026 is proposed.
Advisory vote on executive compensation (Say on Pay) and approval of the 2026 Incentive Compensation Plan are included.
Shareholder proposal to reduce the threshold for the right to act by written consent is presented, with the board recommending against it.
Board of directors and corporate governance
Board recommends all director nominees for election, reflecting ongoing governance and oversight priorities.
Latest events from CVS Health
- Proxy covers director elections, pay alignment, new incentive plan, and Board-opposed proposal.CVS
Proxy filing3 Apr 2026 - Integrated pharmacy, PBM, and digital platforms drive consumer-focused, affordable healthcare.CVS
Leerink Global Healthcare Conference 20269 Mar 2026 - 2025 revenue and EPS exceeded expectations, but earnings hit by goodwill and litigation charges.CVS
Q4 202510 Feb 2026 - Mid-teens EPS CAGR targeted through 2028, with raised guidance and AI-native platform launch.CVS
Investor Day 20253 Feb 2026 - Q2 revenue up 2.6% to $91.2B, but EPS and guidance cut amid Health Care Benefits headwinds.CVS
Q2 20242 Feb 2026 - Revenue up 6.3% to $95.4B, but large charges drove sharp earnings decline.CVS
Q3 202416 Jan 2026 - Leadership and pricing innovations set the stage for cautious but improving financial outlooks.CVS
Wolfe Research 2024 Healthcare Conference13 Jan 2026 - 2025 guidance targets EPS growth and revenue above $385B despite ongoing cost headwinds.CVS
Q4 20248 Jan 2026 - Q1 2025 revenue up 7% to $94.6B; adjusted EPS guidance raised to $6.00–$6.20.CVS
Q1 202520 Dec 2025